RNA Supply Chain Videos

  1. Addressing mRNA's Scalability And Supply Challenges 3/14/2022

    Tune in as Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx share supply chain and manufacturing capacity constraints in the face of the urgency to address COVID-19. This is an excerpt from the Bioprocess Online Live event - mRNA Manufacturing: Bright Future, Big Challenges.

  2. Assessing The Quality & Maturity Of The Next-Gen Oligo Supply Chain 12/3/2025

    As our molecules grow more complicated, so, too, does the supply chain. Here, Advancing RNA Live speakers Khaled Yamout & Camp4’s Satya Kuchimanchi talk through how this growth challenges our understanding of raw material quality and how sponsors can better assess their suppliers.

  3. Analytical Limitations In Assessing Plasmid Quality for mRNA Production 4/11/2025

    There remain a lot of gaps in our understanding of plasmid quality, particularly for high-quality mRNA production (as opposed to viral vector production). In this segment of a recent Advancing RNA Live panel, speakers Adi Nair, Tyler Goodwin, and April Sena highlight their biggest questions around plasmid DNA quality, as well as the pros and cons of some of the analytical methods upon which we’re relying most heavily today to assess plasmid quality.

  4. Why Current dsRNA Analytics Don't Quite Cut It 10/15/2025

    In this Advancing RNA Live segment, several speakers raise concerns about the industry's ability to accurately measure impurities, particularly dsRNA, arguing that current analytics are insufficient, especially for high-dose therapeutics.

  5. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.